Top

Published in:

Open Access 01-12-2014 | Research article

DNA methylation gene-based models indicating independent poor outcome in prostate cancer

Authors: Nataša Vasiljević, Amar S Ahmad, Mangesh A Thorat, Gabrielle Fisher, Daniel M Berney, Henrik Møller, Christopher S Foster, Jack Cuzick, Attila T Lorincz

Published in: BMC Cancer | Issue 1/2014

Abstract

Background

Prostate cancer has a variable clinical behaviour with frequently unpredictable outcome. DNA methylation plays an important role in determining the biology of cancer but prognostic information is scanty. We assessed the potential of gene-specific DNA methylation changes to predict death from prostate cancer in a cohort of untreated men in the UK.

Methods

This was a population-based study in which cases were identified from six cancer registries in Great Britain. DNA was extracted from formalin-fixed paraffin wax-embedded transurethral prostate resection tissues collected during 1990-96 from men with clinically-localised cancer who chose not to be treated for at least 6 months following diagnosis. The primary end point was death from prostate cancer. Outcomes were determined through medical records and cancer registry records. Pyrosequencing was used to quantify methylation in 13 candidate genes with established or suggested roles in cancer. Univariate and multivariate Cox models were used to identify possible predictors for prostate cancer-related death.

Results

Of 367 men, 99 died from prostate cancer during a median of 9.5 years follow-up (max = 20). Univariately, 12 genes were significantly associated with prostate cancer mortality, hazard ratios ranged between 1.09 and 1.28 per decile increase in methylation. Stepwise Cox regression modelling suggested that the methylation of genes HSPB1, CCND2 and DPYS contributed objective prognostic information to Gleason score and PSA with respect to cancer-related death during follow-up (p = 0.006).

Conclusion

Methylation of 13 genes was analysed in 367 men with localised prostate cancer who were conservatively treated and stratified with respect to death from prostate cancer and those who survived or died of other causes. Of the 13 genes analysed, differential methylation of HSPB1, CCND2 and DPYS provided independent prognostic information. Assessment of gene-methylation may provide independent objective information that can be used to segregate prostate cancers at diagnosis into predicted behavioural groups.

Available only for authorised users

Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P, Transatlantic Prostate Group: Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer. 2006, 95 (9): 1186-1194. 10.1038/sj.bjc.6603411.CrossRefPubMedPubMedCentral

Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P: Standardization of Gleason grading among 337 European pathologists. Histopathology. 2013, 62 (2): 247-256. 10.1111/his.12008.CrossRefPubMed

Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987, 317 (15): 909-916. 10.1056/NEJM198710083171501.CrossRefPubMed

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, Investigators E: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009, 360 (13): 1320-1328. 10.1056/NEJMoa0810084.CrossRefPubMed

Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, Donovan JL, Hamdy FC, Martin RM, Neal DE: Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 2009, 104 (11): 1592-1598. 10.1111/j.1464-410X.2009.08652.x.CrossRefPubMed

Foster CS, Cooper CS: Urgent need to develop independent biomarkers for functional, diagnostic and prognostic application in oncology research. Biomark Med. 2009, 3 (4): 329-333. 10.2217/bmm.09.25.CrossRefPubMed

Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009, 10 (5): 295-304. 10.1038/nrg2540.CrossRefPubMed

Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349 (21): 2042-2054. 10.1056/NEJMra023075.CrossRefPubMed

Yang M, Park JY: DNA methylation in promoter region as biomarkers in prostate cancer. Methods Mol Biol. 2012, 863: 67-109. 10.1007/978-1-61779-612-8_5.CrossRefPubMedPubMedCentral

10.

Rodriguez-Paredes M, Esteller M: Cancer epigenetics reaches mainstream oncology. Nat Med. 2011, 17 (3): 330-339.CrossRefPubMed

11.

Berdasco M, Esteller M: Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010, 19 (5): 698-711. 10.1016/j.devcel.2010.10.005.CrossRefPubMed

12.

Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F: EAU guidelines on prostate cancer. Eur Urol. 2008, 53 (1): 68-80. 10.1016/j.eururo.2007.09.002.CrossRefPubMed

13.

Jeronimo C, Henrique R: Epigenetic biomarkers in urological tumors: a systematic review. Cancer Lett. 2014, 342 (2): 264-274. 10.1016/j.canlet.2011.12.026.CrossRefPubMed

14.

Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM: Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci. 2007, 12: 4254-4266. 10.2741/2385.CrossRefPubMed

15.

Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009, 27 (5): 549-560. 10.1080/07357900802620794.CrossRefPubMedPubMedCentral

16.

Banez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, Ittmann MM, Lark AL, Madden JF, Hartman A, Weiss G, Castanos-Velez E: Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010, 184 (1): 149-156. 10.1016/j.juro.2010.03.012.CrossRefPubMed

17.

Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B: Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011, 129 (10): 2454-2462. 10.1002/ijc.25908.CrossRefPubMed

18.

Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA: MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer. 2008, 99 (11): 1802-1807. 10.1038/sj.bjc.6604777.CrossRefPubMedPubMedCentral

19.

Vasiljevic N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Moller H, Yu Y, Lu YJ, Cuzick J, Foster CS, Lorincz AT: Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer. Prostate Cancer Prostatic Dis. 2012, 16 (1): 35-40.CrossRefPubMedPubMedCentral

20.

Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat M, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011, 30 (4): 151-161. 10.1155/2011/157829.CrossRefPubMed

21.

Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O, Tos AG, Merletti F: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol. 2009, 27 (19): 3161-3168. 10.1200/JCO.2008.18.2485.CrossRefPubMed

22.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D: Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005, 11 (23): 8321-8325. 10.1158/1078-0432.CCR-05-1183.CrossRefPubMed

23.

Kloth M, Goering W, Ribarska T, Arsov C, Sorensen KD, Schulz WA: The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer. Int J Cancer. 2012, 131 (6): E897-E904. 10.1002/ijc.27628.CrossRefPubMed

24.

Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL: Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004, 113 (6): 913-923. 10.1172/JCI20032.CrossRefPubMedPubMedCentral

25.

Parkin DM, Whelan SL, Ferlay J, Raymomd L, Young J: Cancer Incidence in five continents. IARC Scientific Publication no 155. 2002

26.

Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ: Distinct genomic alterations in prostate cancers in Chinese and western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010, 70 (13): 5207-5212. 10.1158/0008-5472.CAN-09-4074.CrossRefPubMedPubMedCentral

27.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006, 100 (2): 229-235. 10.1007/s10549-006-9242-8.CrossRefPubMed

28.

Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser. 1995, 57 (1): 289-300.

29.

Erfon B, Tibshirani R: An Introduction to the Bootstrap. 1993, New York: Chapman and Hall

30.

Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000, 60 (24): 7099-7105.PubMed

31.

Foster CS, Dodson AR, Ambroisine L, Fisher G, Moller H, Clark J, Attard G, De-Bono J, Scardino P, Reuter VE, Cooper CS, Berney DM, Cuzick J: Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer. 2009, 101 (7): 1137-1144. 10.1038/sj.bjc.6605227.CrossRefPubMedPubMedCentral

32.

Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007, 13 (20): 6122-6129. 10.1158/1078-0432.CCR-07-1042.CrossRefPubMed

33.

Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP: Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One. 2008, 3 (4): e2079-10.1371/journal.pone.0002079.CrossRefPubMedPubMedCentral

34.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA: Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn. 2004, 4 (4): 513-526. 10.1586/14737159.4.4.513.CrossRefPubMed

35.

Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM: Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008, 68 (10): 3584-3590. 10.1158/0008-5472.CAN-07-6154.CrossRefPubMedPubMedCentral

36.

Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J: Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer. 2009, 100 (6): 888-893. 10.1038/sj.bjc.6604951.CrossRefPubMedPubMedCentral

37.

Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Moller H, Scardino P, Warren JD, Park J, Younus A, Flake DD, Wagner S, Gutin A, Lanchbury JS, Stone S, Transatlantic Prostate G: Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011, 12 (3): 245-255. 10.1016/S1470-2045(10)70295-3.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/655/prepub

Title: DNA methylation gene-based models indicating independent poor outcome in prostate cancer
Authors: Nataša Vasiljević
Amar S Ahmad
Mangesh A Thorat
Gabrielle Fisher
Daniel M Berney
Henrik Møller
Christopher S Foster
Jack Cuzick
Attila T Lorincz
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-14-655

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Combined use of the automated breast volume scanner and the US elastography for the differentiation of benign from malignant lesions of the breast

Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer

Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma

Interest of preoperative immunonutrition in liver resection for cancer: study protocol of the PROPILS trial, a multicenter randomized controlled phase IV trial

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer